889 related articles for article (PubMed ID: 27994453)
1. Drop in lung function during asthma and COPD exacerbations - can it be assessed without spirometry?
Melbye H; Al-Ani S; Spigt M
Int J Chron Obstruct Pulmon Dis; 2016; 11():3145-3152. PubMed ID: 27994453
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome.
Lee SY; Park HY; Kim EK; Lim SY; Rhee CK; Hwang YI; Oh YM; Lee SD; Park YB
Int J Chron Obstruct Pulmon Dis; 2016; 11():2797-2803. PubMed ID: 27877033
[TBL] [Abstract][Full Text] [Related]
3. Predictors of treatment with antibiotics and systemic corticosteroids for acute exacerbations of asthma and chronic obstructive pulmonary disease in primary care.
Salwan AA; Spigt M; Laue J; Melbye H
BMC Fam Pract; 2015 Mar; 16():40. PubMed ID: 25887285
[TBL] [Abstract][Full Text] [Related]
4. Exacerbations and health care resource utilization in patients with airflow limitation diseases attending a primary care setting: the PUMA study.
Montes de Oca M; Aguirre C; Lopez Varela MV; Laucho-Contreras ME; Casas A; Surmont F
Int J Chron Obstruct Pulmon Dis; 2016; 11():3059-3067. PubMed ID: 27994446
[TBL] [Abstract][Full Text] [Related]
5. Impact of exacerbations on respiratory system impedance measured by a forced oscillation technique in COPD: a prospective observational study.
Kamada T; Kaneko M; Tomioka H
Int J Chron Obstruct Pulmon Dis; 2017; 12():509-516. PubMed ID: 28223791
[TBL] [Abstract][Full Text] [Related]
6. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
7. Should pulse oximetry be included in GPs' assessment of patients with obstructive lung disease?
Dalbak LG; Straand J; Melbye H
Scand J Prim Health Care; 2015; 33(4):305-10. PubMed ID: 26654760
[TBL] [Abstract][Full Text] [Related]
8. The objective evaluation of obstructive pulmonary diseases with spirometry.
Ozkaya S; Dirican A; Tuna T
Int J Chron Obstruct Pulmon Dis; 2016; 11():2009-15. PubMed ID: 27616884
[TBL] [Abstract][Full Text] [Related]
9. Low FEV1, smoking history, and obesity are factors associated with oxygen saturation decrease in an adult population cohort.
Vold ML; Aasebø U; Melbye H
Int J Chron Obstruct Pulmon Dis; 2014; 9():1225-33. PubMed ID: 25364242
[TBL] [Abstract][Full Text] [Related]
10. Bronchodilator response of advanced lung function parameters depending on COPD severity.
Jarenbäck L; Eriksson G; Peterson S; Ankerst J; Bjermer L; Tufvesson E
Int J Chron Obstruct Pulmon Dis; 2016; 11():2939-2950. PubMed ID: 27932874
[TBL] [Abstract][Full Text] [Related]
11. Asthma-COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study.
Montes de Oca M; Victorina Lopez Varela M; Laucho-Contreras ME; Casas A; Schiavi E; Mora JC
BMC Pulm Med; 2017 Apr; 17(1):69. PubMed ID: 28431499
[TBL] [Abstract][Full Text] [Related]
12. Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease.
Fortis S; Comellas A; Make BJ; Hersh CP; Bodduluri S; Georgopoulos D; Kim V; Criner GJ; Dransfield MT; Bhatt SP;
Ann Am Thorac Soc; 2019 Jul; 16(7):826-835. PubMed ID: 30908927
[No Abstract] [Full Text] [Related]
13. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.
Thomsen M; Ingebrigtsen TS; Marott JL; Dahl M; Lange P; Vestbo J; Nordestgaard BG
JAMA; 2013 Jun; 309(22):2353-61. PubMed ID: 23757083
[TBL] [Abstract][Full Text] [Related]
14. A year in the life of German patients with COPD: the DACCORD observational study.
Buhl R; Criée CP; Kardos P; Vogelmeier C; Lossi N; Mailänder C; Worth H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1639-46. PubMed ID: 27499620
[TBL] [Abstract][Full Text] [Related]
15. Detection of COPD in a high-risk population: should the diagnostic work-up include bronchodilator reversibility testing?
Kjeldgaard P; Dahl R; Løkke A; Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2015; 10():407-14. PubMed ID: 25759573
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma.
Richter DC; Joubert JR; Nell H; Schuurmans MM; Irusen EM
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):693-9. PubMed ID: 19281083
[TBL] [Abstract][Full Text] [Related]
17. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
[TBL] [Abstract][Full Text] [Related]
18. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
19. Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?
Dreyse J; Díaz O; Repetto PB; Morales A; Saldías F; Lisboa C
Int J Chron Obstruct Pulmon Dis; 2015; 10():525-33. PubMed ID: 25792820
[TBL] [Abstract][Full Text] [Related]
20. Measures of bronchodilator response of FEV
Torén K; Bake B; Olin AC; Engström G; Blomberg A; Vikgren J; Hedner J; Brandberg J; Persson HL; Sköld CM; Rosengren A; Bergström G; Janson C
Int J Chron Obstruct Pulmon Dis; 2017; 12():973-980. PubMed ID: 28356729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
